[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qilu Hospital of Shandong University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":637},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,127,0,25,[9,42,77,99,129,151,175,200,225,246,271,292,319,347,373,404,426,450,473,496,520,540,560,586,611],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100603452","risk-factors-prognosis-clinicopathological-and-metabolic-characteristics-of-eo--vs-lo-pannets-100603452",false,"NCT07136701","Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs","Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study","Inclusion Criteria:\n\n* 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.\n\nExclusion Criteria:\n\n* Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.","ALL","18 Years","85 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).\n\nThe main questions it aims to answer are:\n\nAre there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.\n\nParticipants will:\n\nProvide retrospective clinical, pathological, and metabolic data from hospital records.\n\nHave survival and recurrence outcomes assessed through follow-up data review.",[26],"Pancreatic Neuroendocine Neoplasms (pNETs)",[28],"EO-PanNET","RECRUITING","2026-08-11",{"date":32,"type":33},"2026-08-13","ACTUAL",{"date":35,"type":33},"2025-08-31",{"date":37,"type":22},"2027-07-31",{"name":39,"class":40},"Qilu Hospital of Shandong University","OTHER",2,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100651448","prophylactic-iabp-in-delayed-presentation-anterior-stemi-100651448","NCT07761455","Prophylactic IABP in Delayed-Presentation Anterior STEMI","Prophylactic Intra-Aortic Balloon Counterpulsation for Delayed-Presentation Anterior ST-Segment Elevation Myocardial Infarction: A Prospective, Multicenter, Randomized Controlled Trial (PROACTIVE-AMI)","PROACTIVE-AMI","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. First electrocardiogram on arrival shows ST-segment elevation ≥ 2 mm in at least two contiguous anterior leads, or sum of ST-segment elevation ≥ 4 mm in anterior leads.\n3. Ischemic symptoms (chest pain, chest tightness, upper abdominal discomfort, left shoulder radiation, etc.) onset to hospital arrival between ≥ 4 hours and ≤ 12 hours, and planned for primary PCI.\n4. Coronary angiography confirms the infarct-related artery is the proximal left anterior descending (LAD) (before the first septal branch or first diagonal branch) with TIMI flow grade 0 (total occlusion).\n5. Patient or legal representative provides written informed consent.\n\nExclusion Criteria:\n\n1. Established cardiogenic shock (systolic blood pressure \\\u003C 90 mmHg without inotropes\u002Fvasopressors, or requiring vasopressors to maintain systolic blood pressure ≥ 90 mmHg, AND blood lactate \\> 2.0 mmol\u002FL).\n2. Severe heart failure: Killip class ≥ III, or requiring non-invasive\u002Finvasive positive pressure ventilation before enrollment.\n3. Malignant arrhythmias, including cardiac arrest, ventricular fibrillation, ventricular flutter, pulseless ventricular tachycardia, or high-grade atrioventricular block.\n4. Severe mechanical complications (e.g., free wall rupture, ventricular septal defect, acute severe mitral regurgitation).\n5. Contraindications to IABP (severe peripheral vascular disease, aortic dissection, known aortic aneurysm, moderate-to-severe aortic regurgitation).\n6. Prior myocardial infarction or known chronic heart failure (left ventricular ejection fraction \\\u003C 50%).\n7. Prior coronary artery bypass grafting (CABG).\n8. Stroke within 1 month, or history of hemorrhagic stroke at any time.\n9. Active gastrointestinal bleeding within 3 months, or gastrointestinal diseases with increased bleeding risk.\n10. Received thrombolytic therapy for this episode.\n11. Initiation of any mechanical circulatory support (IABP, Impella, ECMO) before coronary angiography.\n12. Severe hepatic insufficiency (Child-Pugh C, or ALT \\>5×ULN with total bilirubin \\>3×ULN), renal insufficiency (eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m² or chronic dialysis), or end-stage disease with life expectancy \\\u003C 1 year.\n13. Pregnancy or lactation.\n14. Currently participating in another interventional trial.",{"count":51,"type":22},504,"INTERVENTIONAL",[54],"NA","PROACTIVE-AMI is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication evaluating whether prophylactic intra-aortic balloon counterpulsation (IABP) initiated before primary percutaneous coronary intervention (PPCI) improves clinical outcomes in patients with delayed-presentation acute anterior ST-segment elevation myocardial infarction (STEMI). Eligible patients are adults aged ≥18 years who present 4 to 12 hours after symptom onset, have electrocardiographic evidence of anterior STEMI with proximal left anterior descending artery total occlusion (TIMI flow 0), and are planned for PPCI. Participants will be randomized 1:1 to pre-PPCI IABP plus standard PPCI or standard PPCI alone. The primary endpoint is 180-day major adverse cardiovascular events (MACE), defined as a composite of all-cause death, cardiogenic shock, and new or worsening heart failure. Secondary outcomes include individual MACE components, cardiac death, length of stay, NT-proBNP, left ventricular ejection fraction, and left ventricular end-diastolic volume. Safety outcomes include major bleeding, vascular complications, thrombocytopenia, and stroke.",[57],"Acute Anterior ST-Segment Elevation Myocardial Infarction",[59,60,61,62,63,64,65,66],"STEMI","Anterior myocardial infarction","Delayed presentation","Intra-aortic balloon pump","IABP","Primary PCI","Percutaneous coronary intervention","Mechanical circulatory support","NOT_YET_RECRUITING","2026-08-10",{"date":70,"type":33},"2026-08-12",{"date":72,"type":22},"2026-08-01",{"date":74,"type":22},"2028-07-31",{"name":39,"class":40},4,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":52,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100651227","phase-4-efficacy-and-safety-of-14-day-vonoprazan-minocycline-dual-therapy-for-helicobacter-pylori-eradication-100651227","NCT07757919","Efficacy and Safety of 14-Day Vonoprazan-Minocycline Dual Therapy for Helicobacter Pylori Eradication","Efficacy and Safety of 14-Day Vonoprazan-Minocycline Dual Therapy for Helicobacter Pylori Eradication: A Multicenter, Non-Inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18-65 years, male or female.\n* Helicobacter pylori-infected patients with positive ¹³C\u002F¹⁴C urea breath test, and at least one positive result among the following three tests: Rapid Urease Test; Histopathological examination of gastric mucosal biopsy specimens; Stool Hp antigen test.\n* No prior history of Helicobacter pylori eradication therapy.\n\nExclusion Criteria:\n\n* Severe underlying diseases, such as hepatic insufficiency, renal insufficiency, malignant tumors, etc.\n* Active gastrointestinal bleeding.\n* History of upper gastrointestinal surgery.\n* History of allergy to study medications.\n* Use of antibiotics or bismuth agents within 1 month, or acid-suppressive agents within 2 weeks.\n* Pregnant or lactating women.\n* Presence of other behaviors that may increase disease risks, such as heavy alcohol consumption, drug abuse, etc.\n* Participation in other clinical trials within 3 months.\n* Subjects unable or unwilling to provide written informed consent.","65 Years",{"count":86,"type":22},492,[88],"PHASE4","Investigators will enroll treatment-naïve H. pylori-positive patients according to the inclusion and exclusion criteria in the trial. After obtaining written informed consent, investigators will open envelopes labeled with corresponding subject numbers in the order of subject enrollment to determine group allocation. Subjects will receive interventions according to their assigned regimens: the 14-day vonoprazan-amoxicillin dual therapy regimen, the 14-day vonoprazan-tetracycline dual therapy regimen, or the 14-day vonoprazan-minocycline dual therapy regimen.\n\nMeanwhile, investigators will complete the case report forms (CRFs) to record subjects' basic demographic information and risk factors for eradication failure. Subjects will be asked to fill out patient diaries to document medication administration and adverse reactions. After trial initiation, investigators will follow up with subjects via telephone or WeChat and collect patient diaries, summarize medication status and adverse reactions during treatment, and assess subject compliance.\n\nSix weeks after the end of treatment, subjects will undergo a repeat ¹³C-urea breath test. Investigators will record treatment outcomes and re-examination results, finalize the case report forms, and upload photographs of original examination documents.\n\nAfter all subjects finish the trial, the eradication rate, incidence of adverse events and subject compliance in each group will be calculated. Statistical analyses will be performed to compare demographic characteristics and risk factors between patients with eradication success and eradication failure. The findings will provide evidence for the selection of H. pylori eradication regimens.",[91],"HELICOBACTER PYLORI INFECTIONS","2026-08-06",{"date":30,"type":33},{"date":95,"type":22},"2026-09-01",{"date":97,"type":22},"2027-12-30",{"name":39,"class":40},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":52,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100651225","clinical-application-of-an-ai-based-dissection-trajectory-prediction-system-adtps-in-endoscopic-submucosal-dissection-100651225","NCT07757906","Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection","Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection: A Prospective Paired Diagnostic Study and a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Chinese patients aged 18-80 years.\n\nLesions meeting ESD indications for esophageal, gastric, or colorectal early cancer or high-grade intraepithelial neoplasia, as defined by:\n\nNon-invasive tumors regardless of size; or\n\nDifferentiated-type intramucosal carcinoma without ulceration, regardless of size; or\n\nDifferentiated-type intramucosal carcinoma with ulceration and a diameter ≤3 cm; or\n\nUndifferentiated-type intramucosal carcinoma without ulceration and a diameter ≤2 cm.\n\nPlanned to undergo ESD treatment.\n\nNo prior treatment for the lesion (including ESD, surgery, radiotherapy, chemotherapy, etc.).\n\nPlatelet count \\>100 × 10⁹\u002FL and PT-INR \\\u003C1.5, with antiplatelet agents (aspirin, clopidogrel, etc.) discontinued for at least 5 days.\n\nAmerican Society of Anesthesiologists (ASA) physical status grade I or II.\n\nVoluntarily signed informed consent.\n\nExclusion Criteria:\n\n* Patients currently undergoing dialysis.\n\nPatients with severe cardiopulmonary disease or other severe comorbidities that may increase the risk of the ESD procedure.\n\nPregnant or breastfeeding women.","80 Years",{"count":108,"type":22},160,[54],"In this prospective paired diagnostic study and single-center, randomized controlled trial, patients with early esophageal squamous neoplasia or high-grade intraepithelial neoplasia meeting the inclusion and exclusion criteria will be enrolled in a paired diagnostic cohort (60 patients) and subsequently randomly assigned (1:1) to receive endoscopic submucosal dissection (ESD) with AI-based Dissection Trajectory Prediction System (ADTPS) guidance or conventional ESD (without AI). Clinical data and operator workload scores (NASA-TLX) are collected during the procedure, and postoperative follow-up assessments are performed at days 1, 3, 7, and 14. The study aims to analyze the impact of ADTPS on the mean single-dissection time and operator workload in patients undergoing ESD by comparing the efficacy differences between the experimental and control groups. Additionally, the study investigates the effects of ADTPS on other postoperative complications including R0 resection rate, muscularis propria injury, intraoperative bleeding, perforation (acute and delayed), and total procedure time; conducts a comparative analysis of the safety and efficiency of AI-assisted versus conventional ESD; and develops effective clinical strategies for optimizing dissection trajectory and reducing complications in endoscopic submucosal dissection.",[112,113,114],"Esophageal Squamous Cell Carcinoma (ESCC)","High-Grade Intraepithelial Neoplasia","AI-Based Dissection Trajectory Prediction System",[116,117,118,119,120,121,122],"Artificial intelligence","R0 resection","Procedural efficiency","NASA-TLX","Randomized controlled trial","Dissection trajectory prediction","Endoscopic submucosal dissection",{"date":30,"type":33},{"date":125,"type":22},"2026-07-29",{"date":127,"type":22},"2027-10-01",{"name":39,"class":40},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100634713","an-artificial-intelligence-system-for-multimodal-multi-class-diagnosis-of-pancreatic-cystic-lesions-based-on-endoscopic-ultrasonography-100634713","NCT07543263","An Artificial Intelligence System for Multimodal, Multi-class Diagnosis of Pancreatic Cystic Lesions Based on Endoscopic Ultrasonography","Inclusion Criteria:\n\n1. Patients aged ≥18 years scheduled for EUS with suspected pancreatic cystic lesions based on clinical symptoms, medical history, laboratory tests or radiological examinations, and who agree to participate in the research and voluntarily sign the informed consent.\n2. Patients with no prior history of treatment for pancreatic lesions.\n\nExclusion Criteria:\n\n1. Patients with absolute contraindications to EUS examination.\n2. Pregnancy or lactating.\n3. Uncorrectable coagulopathy (PTT\\>50 seconds or INR\\>1.5) and\u002For uncorrectable thrombocytopenia(platelet count\\\u003C50×109\u002FL).\n4. Upper gastrointestinal obstruction.\n5. Patients who underwent surgical treatment or anatomical alterations of the pancreas due to lesions in other thoracic and\u002For abdominal organs, as well as patients with congenital anatomical abnormalities.\n6. Patients who have undergone biliary\u002Fpancreatic duct stent placement.\n7. Patients who refuse to sign the informed consent.",{"count":136,"type":22},176,"The aim of this study is to develop and validate an artificial intelligence system named iEUS-PCL (intelligent endoscopic ultrasound system-pancreatic cystic lesions） for detecting and multimodal, multi-class diagnosing pancreatic cystic lesions (PCL) during endoscopic ultrasound (EUS) examination.",[139],"Pancreatic Cystic Lesion (PCL)",[141,142,143],"endoscopic ultrasound","pancreatic cystic lesion","machine learning",{"date":68,"type":33},{"date":146,"type":33},"2026-04-20",{"date":148,"type":22},"2028-06-30",{"name":39,"class":40},1,{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":158,"targetDuration":4,"studyType":52,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":150},"100630486","the-effect-of-proton-pump-inhibitorsppis-on-endoscopic-treatment-of-walled-off-necrosis-won-100630486","NCT07488299","The Effect of Proton Pump Inhibitors(PPIs) on Endoscopic Treatment of Walled-off Necrosis (WON)","The Effect of Proton Pump Inhibitors on Endoscopic Treatment of Walled-off Necrosis: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients aged 18 years or older and not exceeding 80 years of age.\n2. Patients with a confirmed diagnosis of WON.\n3. Patients requiring endoscopic ultrasound-guided transluminal drainage\u002Fdebridement therapy.\n4. Patients who have signed informed consent forms.\n\nExclusion Criteria:\n\n1. Patients diagnosed with chronic pancreatitis who have not experienced an acute pancreatitis attack within the past three months.\n2. Patients with severe coagulation disorders (International Normalized Ratio \\[INR\\] \\> 1.5).\n3. Patients with significant thrombocytopenia (platelet count \\\u003C 50 × 10\\^9\u002FL).\n4. Pregnant women.\n5. Patients undergoing endoscopic drainage solely through the duodenum.\n6. Patients with a history of gastrectomy, gastric bypass surgery, or prior surgery for pancreatic-related diseases.\n7. Patients currently taking medications that may affect gastric acid secretion or metabolism, such as strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., clarithromycin, itraconazole) or inducers (e.g., rifampin, carbamazepine).\n8. Patients requiring long-term use of acid-suppressing medications such as PPIs and P-CABs due to other medical conditions.\n9. Patients with a history of acid-suppressive medication use (e.g., PPI) and a washout period of less than 14 days.\n10. Patients with documented contraindications to PPIs or a relevant history of hypersensitivity.",{"count":159,"type":22},120,[54],"In this multicenter, randomized controlled trial, patients with pancreatic walled-off necrosis (WON) based on inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to either receive intravenous infusion or oral administration of continuous proton pump inhibitors (PPIs) or to undergo no PPI (nPPI) therapy after endoscopic ultrasound-guided transluminal drainage\u002Fdebridement. Clinical data and patient-reported outcomes will be systematically collected at baseline and during follow-up periods. The study aims to assess whether PPI use after EUS-TD (Endoscopic Ultrasonography-Guided Transmural Drainage) increases the number of direct endoscopic necrosectomies required to managing WON. Additionally, the study will investigate the impact of PPI use on the incidence of stent occlusion and postoperative complications following EUS-TD, as well as its effect on the average duration of hospitalization and associated costs for patients with WON.",[163],"Pancreatic Walled-off Necrosis",[163,165,166,167,168],"Direct Endoscopic Necrosectomy","Proton Pump Inhibitor","Randomized Controlled Trial","Endoscopic Ultrasound-guided Transluminal Drainage\u002FDebridement",{"date":68,"type":33},{"date":171,"type":33},"2025-09-17",{"date":173,"type":22},"2028-03-20",{"name":39,"class":40},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":182,"targetDuration":4,"studyType":52,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":150},"100570194","virtual-reality-task-oriented-training-on-upper-limb-function-in-stroke-patients-100570194","NCT06704074","Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients","Effectiveness of Real Home Settings Via Virtual Reality Task Oriented Training on Upper Llimb Function in Patients With Stroke: A Multicenter, Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n-1. Ischemic or hemorrhagic stroke was diagnosed based on the history, symptoms, and signs combined with CT or MRI imaging; 2. First stroke, onset time from 1 to 6 months, age ≥ 18 - 80 years ; 3. Hemiplegia, Brunnstrom stage ≥ Ⅱ - Ⅴ, modified Ashworth grade \\\u003C 4; 4. Able to maintain sitting balance (with no or only minimal assistance) for at least 30 minutes to facilitate assessment and training; 5. No significant unilateral neglect (confirmed by tests such as the Schenkenberg Line Bisection Test); visual or corrected vision and hearing must be sufficient to meet the requirements for VR training and to understand instructions.\n\n6.Patients or their family members signed informed consent to participate in the experiment.\n\nExclusion Criteria:\n\n* 1\\. Previous history of stroke, traumatic or non-vascular encephalopathy; 2. MOCA ≤ 17, and no sensory aphasia. 3. Skull defect or allogeneic repair; 4. combined with other neurological and mental diseases; 5. Previous diseases that may cause upper limb motor\u002Fsensory dysfunction, such as neck tumor or radiotherapy and chemotherapy history, cervical spondylosis, cervical spine or upper limb fracture history, traumatic brachial plexus injury history, arthritis, diabetes mellitus, myasthenia gravis, multiple sclerosis, etc.\n\n  6\\. Accompanied by obvious vertigo or dizziness symptoms or related diseases (such as motion sickness, Meniere's syndrome, otolithiasis, etc.); 6. Accompanied by obvious pain; 7. Significant pain in the affected upper limb or shoulder at rest or during activity (VAS ≥ 4 ) 8. Evidence of ataxia and cerebellar or brainstem lesions according to the NIHSS; 9. Ongoing participation in other clinical investigators; 10. Unstable condition, refusal to sign the informed consent, and unwillingness to cooperate with the examination and treatment.",{"count":183,"type":22},86,[54],"Stroke rank second among the top causes of death, affecting millions of people in the worldwide. It has been reported that hemiplegia is the most common sequelae after stroke, accounting for about 50%-70% of all sequelae of the disease. About 75% of stroke patients are accompanied by different degrees of upper limb dysfunction, which seriously affects the activities of daily life and cause serious physical and mental burden to patients and their families. Early recovery of upper limb motor function is a great significance for the overall recovery of stroke patients. Task-oriented training (TOT) is reported to improve the motor coordination and ADL. However, lack varies of tasks limited the treatment ability for patients with stroke hemiplegia during hospital admission. Virtual reality (VR) offers advantages of providing virtual scenes that is difficult in the real world, such as the scene of garden, camara, and plaza etc. And the familiar circumstances for patients may have the potential to increase the motivation of rehabilitation training, and improve the efficacy of occupational therapy (OT).\n\nThe goal of this study is to observe the effectiveness of real home settings via virtual reality assisted TOT on upper limb function in patients with stroke. Functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) were used to observe the changes in brain function under VR-TOT training.\n\nWe intended to recruit 120 participants, and allocate to three groups: VR-TOT, TOT, and traditional OT. Each of them completed the Fugl-Meyer-UE, Wolf motor function test (WMFT), hand gripping power, modified Ashworth、Purdue Pegboard test （PPT）、modified Barthel index (MBI)、mini mental state examination (MMSE)、NIH stroke scale (NIHSS)、Virtual reality sickness questionnaire (VRSQ), Intrinsic Motivation Inventory Inventory (IMI), satisfaction VAS, body representation, sense of ownership, Proprioceptive Drift scale before and after the treatment. Additionally, we conducted fNIRS and EEG at baseline and during the follow up to understand the changes in brain function.",[187],"Stroke",[189,190,191,192,193],"stroke","rehabilitation","Task-oriented training (TOT)","virtual reality (VR)","upper limb dysfunction",{"date":68,"type":33},{"date":196,"type":33},"2026-05-09",{"date":198,"type":22},"2026-11-30",{"name":39,"class":40},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":52,"phases":210,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100650545","phase-4-optimizing-h-pylori-eradication-regimen-under-intensified-acid-suppression-100650545","NCT07750938","Optimizing H. Pylori Eradication Regimen Under Intensified Acid Suppression","Intensified Acid Suppression Strategy for Optimizing Helicobacter Pylori Eradication Regimen Duration and Drug Combination: A Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 70 years, male or female.\n* Confirmed H. pylori infection, defined as a positive 13C-urea breath test (13C-UBT) plus at least one positive result from the following: stool H. pylori antigen test, rapid urease test, or gastric mucosal histopathology.\n* No prior history of H. pylori eradication therapy.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any of the study drugs (keverprazan, amoxicillin, minocycline, bismuth).\n* Acute upper gastrointestinal bleeding, active gastric or duodenal ulcer, acute gastric mucosal injury, or acute duodenal mucosal injury at screening.\n* Severe underlying diseases, including: hepatic or renal insufficiency; immunosuppression; malignancy; severe central nervous system, cardiovascular, or respiratory diseases.\n* Use of antibiotics, bismuth-containing preparations, or Chinese herbal medicines with antimicrobial effects within 4 weeks prior to the screening 13C-UBT; use of proton pump inhibitors (PPIs) or potassium-competitive acid blockers (P-CABs) within 2 weeks prior to the screening 13C-UBT.\n* Risk behaviors such as drug abuse or alcohol dependence.\n* Pregnancy, breastfeeding, or unwillingness to use contraception during the study period.\n* Current use of atazanavir sulfate or rilpivirine hydrochloride at screening.\n* Requirement during the 14-day treatment period for any of the following medications: ergotamine, dihydroergotamine, probenecid, allopurinol, or methotrexate.\n* Inability or unwillingness to provide informed consent.","70 Years",{"count":209,"type":22},316,[88],"Background:\n\nHelicobacter pylori (H. pylori) infection affects approximately 50% of the global population and is closely associated with chronic gastritis, peptic ulcer disease, and gastric cancer. Eradication of H. pylori can reduce the overall risk of gastric cancer by 39%. Current international guidelines recommend bismuth-containing quadruple therapy as first-line treatment; however, its complex regimen, adverse effects, cost, and suboptimal patient adherence limit its clinical application. Potent acid suppression is essential for H. pylori eradication, as maintaining an intragastric pH of 6-8 enhances the stability of acid-labile antibiotics and promotes bacterial replication, thereby increasing antibiotic susceptibility. Potassium-competitive acid blockers (P-CABs), such as vonoprazan, provide rapid, potent, and sustained acid suppression with dose-dependent effects. Keverprazan hydrochloride is a novel P-CAB with demonstrated dose-dependent acid suppression and favorable safety profiles in Phase I and Phase III studies. Whether an intensified P-CAB dosing strategy can allow treatment shortening and regimen simplification while maintaining high eradication rates warrants investigation.\n\nObjective:\n\nTo evaluate the efficacy and safety of a 10-day high-dose keverprazan dual therapy versus a standard 14-day keverprazan-based bismuth quadruple therapy for first-line H. pylori eradication.\n\nStudy Design:\n\nThis is a multicenter, open-label, randomized controlled trial. Eligible participants (aged 18-70 years with confirmed H. pylori infection and no prior eradication history) will be randomly assigned in a 1:1 ratio to one of two treatment arms:\n\nArm A (Dual therapy, 10 days): Keverprazan 20 mg three times daily plus minocycline 100 mg twice daily.\n\nArm B (Quadruple therapy, 14 days): Keverprazan 20 mg twice daily, bismuth potassium citrate 240 mg twice daily, amoxicillin 1000 mg twice daily, and minocycline 100 mg twice daily.\n\nThe primary efficacy assessment will be performed at 6 weeks post-treatment using the 13C-urea breath test. A total of 316 participants (158 per arm) will be enrolled, accounting for an estimated 10% dropout rate.\n\nOutcome Measures:\n\nPrimary Outcome: H. pylori eradication rate at 6 weeks after completion of treatment.\n\nSecondary Outcomes: Safety and tolerability (adverse events, laboratory abnormalities) and treatment adherence.",[91],[214,215,216,217,218],"minocycline","helicobacter pylori","10 day","dual therapy","keverprazan","2026-08-03",{"date":92,"type":33},{"date":72,"type":22},{"date":223,"type":22},"2028-08-10",{"name":39,"class":40},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":234,"targetDuration":236,"studyType":23,"phases":4,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":4},"100649914","the-fecal-immunoassay-occult-blood-test-combined-with-calprotectin-sequential-linkage-imaging-endoscopy-screening-strategy-for-monitoring-tumor-changes-associated-with-long-duration-ulcerative-colitis-100649914","NCT07742410","The Fecal Immunoassay Occult Blood Test Combined With Calprotectin Sequential Linkage Imaging Endoscopy Screening Strategy for Monitoring Tumor Changes Associated With Long-duration Ulcerative Colitis","Diagnostic Performance of Fecal Immunochemical Test Combined With Fecal Calprotectin Sequential Linked Color Imaging Endoscopy for Surveillance of Colitis-Associated Neoplasia in Long-standing Ulcerative Colitis: A Multicenter, Prospective Cohort Study","DETECT-UCAN","Inclusion Criteria:\n\n* Age 18-75 years, any gender.\n* Definite diagnosis of ulcerative colitis by clinical, endoscopic, and pathological criteria.\n* Meeting at least one of the following high-risk criteria (with first onset of mucopurulent bloody stool as the starting time): E1\u002FE2 disease duration \\>10 years; E3 disease duration \\>8 years; with primary sclerosing cholangitis (PSC); first-degree family history of colorectal cancer; history of colorectal neoplasia resected.\n* Discontinued any form of glucocorticoids for at least 4 weeks prior to enrollment.\n* In clinical remission at enrollment (stool frequency score \\\u003C3, rectal bleeding score = 0).\n* Able to understand the study, voluntarily participate, and sign written informed consent.\n\nExclusion Criteria:\n\n* Presence of other gastrointestinal diseases or tumors.\n* Severe comorbidities (e.g., cardiopulmonary insufficiency, hepatic or renal failure) that may affect study results or preclude tolerance of endoscopy.\n* Currently taking antiplatelet or anticoagulant medications (aspirin, warfarin, rivaroxaban, etc.).\n* Pregnant or breastfeeding women.\n* History of total or subtotal colectomy.","75 Years",{"count":235,"type":22},250,"12 Months","Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with an increased risk of colorectal cancer, known as UC-associated neoplasia (UCAN). Current guidelines recommend regular colonoscopy surveillance for long-standing UC patients, but this strategy faces challenges including poor adherence and low neoplasia detection rates. This study aims to evaluate the diagnostic performance of a non-invasive pre-screening strategy combining fecal immunochemical test (FIT) and fecal calprotectin (FC), followed by linked color imaging (LCI) colonoscopy, for detecting UCAN in patients with long-standing UC.\n\nThis is a multicenter, prospective, diagnostic cohort study. Eligible patients with long-standing UC (disease duration \\>8 years for extensive colitis or \\>10 years for left-sided colitis, or with PSC) will undergo FIT and FC testing, followed by LCI colonoscopy within 4 weeks regardless of stool test results. The primary outcome is the diagnostic performance (sensitivity, specificity, PPV, NPV) of combined FIT+FC testing for UCAN, using LCI colonoscopy with histopathology as the reference standard. A total of 250 participants will be enrolled from 6 centers in China. Secondary outcomes include UCAN detection rate, feasibility indicators, patient adherence and acceptability, optimal cut-off values for FIT and FC, and 12-month miss rate.",[239],"Ulcerative Colitis (UC)",{"date":219,"type":33},{"date":242,"type":22},"2026-07-23",{"date":244,"type":22},"2029-12-31",{"name":39,"class":40},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":150},"100601521","fecal-biomarker-response-evaluation-for-super-early-efficacy-in-ulcerative-colitis-100601521","NCT07111572","Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis","Dynamic Changes of Fecal Calprotectin and Fecal Immunochemical Test for Early Prediction of Biologic Treatment Efficacy in Ulcerative Colitis: A Multicenter, Prospective Cohort Study","FORESEE-UC","Inclusion Criteria:\\*\\*\n\n* Age 18-75 years, UC diagnosis with endoscopic Mayo score (MES) ≥2\n* Moderate-to-severe activity (Full Mayo Score ≥6)\n* Initiating vedolizumab or infliximab within 7 days after baseline\n* Biologic-naïve or prior exposure to only one TNF-α inhibitor\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n* Pregnancy\u002Flactation\n* Contraindications to biologics (e.g., active TB, severe infection)\n* Experimental drug use within 4 weeks prior to baseline",{"count":255,"type":22},100,"This multicenter prospective cohort aims to evaluate whether combined changes in fecal calprotectin (FC) and fecal immunochemical test (FIT) at \\*\\*Week 2 and Week 4\\*\\* after initiating biologic therapy (vedolizumab or infliximab) can predict clinical response at \\*\\*Week 14\\*\\* and mucosal healing at \\*\\*Week 52\\*\\* in moderate-to-severe ulcerative colitis (UC) patients. Primary outcome: clinical remission rate at Week 14.",[239,258,259],"Fecal Calprotetin","FIT",[261,262,259],"UC","fecal calprotectin","2026-07-27",{"date":265,"type":33},"2026-07-28",{"date":267,"type":33},"2025-08-01",{"date":269,"type":22},"2026-12-01",{"name":39,"class":40},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":279,"targetDuration":280,"studyType":23,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":289,"leadSponsor":291,"locationsCount":150},"100601498","dynamic-uc-early-qfit-and-calprotectin-change-predicting-relapse-in-biologic-naive-ulcerative-colitis-100601498","NCT07111273","DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis","Diagnostic Value of Quantitative Fecal Immunochemical Test (qFIT) and Calprotectin (FC) Dynamic Changes at 2 Weeks for Predicting 52-Week Relapse or Treatment Escalation in Biologic-Naive Ulcerative Colitis: A Multicenter, Prospective Cohort Study (DYNAMIC-UC)","DYNAMIC-UC","Inclusion Criteria:\n\n* Age 18-75 years.\n* Established diagnosis of Ulcerative Colitis (UC) confirmed by clinical, endoscopic, and histopathological criteria.\n* Endoscopic disease activity (Mayo Endoscopic Subscore ≥ 2) confirmed by colonoscopy during screening.\n* Biologic-naive (no prior exposure to any biologic agent \\[e.g., infliximab, adalimumab, vedolizumab, ustekinumab\\] or JAK inhibitor).\n* No use of systemic corticosteroids (oral or intravenous) within 4 weeks prior to Baseline (Week 0) visit.\n* If using oral or rectal mesalazine\u002F5-ASA preparations, dose must have been stable for ≥2 weeks prior to Baseline (Week 0).\n\nWilling and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosis or high suspicion of Crohn's disease, ischemic colitis, infectious colitis, radiation colitis, intestinal tuberculosis, or other types of colitis.\n\nPresence of other conditions clearly causing intestinal bleeding (e.g., acute hemorrhoidal bleeding, colorectal cancer, large colorectal polyps \\>1cm, intestinal vascular malformations).\n\n* Untreated systemic conditions that may cause intestinal bleeding (e.g., thrombocytopenia \\[PLT \\\u003C50 x 10\\^9\u002FL\\], severe coagulopathy).\n* Regular use of antiplatelet agents (e.g., aspirin, clopidogrel) or anticoagulants (e.g., warfarin, rivaroxaban).\n* Pregnancy or lactation.\n* Any other condition deemed by the investigator to make the patient unsuitable for study participation.",{"count":255,"type":22},"14 Weeks","This multicenter prospective cohort study aims to evaluate whether a \\>50% decrease or normalization of both quantitative fecal immunochemical test (qFIT) and fecal calprotectin (FC) levels at 2 weeks after starting conventional therapy (mesalazine or corticosteroids) can predict clinical relapse or need for biologic\u002FJAK inhibitor therapy escalation by 52 weeks in biologic-naive patients with active ulcerative colitis (UC). Secondary objectives include assessing predictive value at 4 weeks, building dynamic prediction models, conducting health economic evaluation (Number Needed to Test, NNT), and exploring baseline predictors of early biomarker response. Patients will be observed during standard care with stool samples collected at Weeks 0, 2, and 4. Biomarker results will be blinded to clinicians\u002Fpatients until study completion.",[239,258,259,283],"Biomarker",[285,262,259,286],"ulcerative colitis","biologic-naive",{"date":265,"type":33},{"date":267,"type":33},{"date":290,"type":22},"2026-12-30",{"name":39,"class":40},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":299,"targetDuration":301,"studyType":23,"phases":4,"briefSummary":302,"conditions":303,"keywords":306,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":150},"100648560","observation-of-iris-blood-flow-via-octa-in-diabetic-neovascular-glaucoma-100648560","NCT07722910","Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma","Analysis of the Identification Value and Quadrant Characteristics of Iris OCTA Blood Flow Quantification in Type 2 Diabetic Neovascular Glaucoma","Inclusion Criteria:\n\n* Aged ≥ 18 years of age, regardless of gender, with or without type 2 diabetes mellitus and its associated ocular complications; clear consciousness, capable of cooperating with iris OCTA examination (able to stabilize the head to guarantee successful acquisition and interpretable images).\n* Voluntary participation in this study with signed written informed consent.\n* No history of intraocular surgery in the examined eye (including cataract surgery, glaucoma filtering surgery, retinal surgery, etc.).\n* General physical conditions: No acute disease episodes within the recent 3 months (such as acute myocardial infarction, stroke, diabetic ketoacidosis); no severe liver or renal dysfunction (ALT and AST ≤ 2 times the upper limit of normal, serum creatinine ≤ 133 μmol\u002FL).\n\nExclusion Criteria:\n\n* The studied eye suffers from other ocular diseases that may interfere with examination results apart from the disorders specified in Criterion 1 of the inclusion criteria (e.g., uveitis, retinal vein occlusion, high myopia-related fundus lesions, etc.); invasive ocular treatments were administered to the studied eye within the past 6 months (e.g., retinal laser photocoagulation, intravitreal injection, etc.).\n* Subjects complicated with type 1 diabetes mellitus, gestational diabetes mellitus or other specific types of diabetes mellitus; those with autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) or hematological diseases (e.g., leukemia, aplastic anemia); individuals who have taken medications affecting ocular microcirculation (e.g., alprostadil, nitrates) within the past 3 months and are unable to discontinue such drugs.\n* Subjects with severe head tremors and inability to maintain a fixed posture during examination, resulting in substandard OCTA image quality (interpretable area \\\u003C 80%); those with mental disorders or cognitive dysfunction who fail to understand and cooperate with the examination procedures.",{"count":300,"type":22},98,"2 Weeks","The goal of this observational study is to quantify iris blood flow via non-invasive eye scanning for evaluating ocular lesions in adults aged 18 years and older, including healthy volunteers, patients with type 2 diabetes mellitus (T2DM) without fundus lesions, T2DM patients with diabetic retinopathy (DR), and T2DM patients complicated with both DR and neovascular glaucoma (NVG). The main questions it aims to answer are:\n\n* Does iris blood flow fraction at six pupillary quadrants differ significantly among people with different stages of type 2 diabetic eye complications?\n* Are there quadrant-specific and gender-based differences in iris microcirculation changes caused by diabetic eye diseases? If there is a comparison group: Researchers will compare iris blood flow data from four groups (healthy controls, T2DM without DR, T2DM with DR, T2DM with DR + NVG) to see how iris blood circulation changes as diabetic eye conditions get worse, and test whether iris blood flow indicators can help identify patients with neovascular glaucoma.\n\nParticipants will complete the following tasks:\n\n* Provide basic personal information, past medical history and recent laboratory test results from their routine medical records;\n* Receive a painless, non-invasive iris OCTA eye scan to capture iris blood flow images at six quadrants around the pupil.",[304,305],"Neovascular Glaucoma","Type 2 Diabetes",[307,308,309,310,311],"Diabetic retinopathy","Neovascular glaucoma","Optical coherence tomography angiography","Iris vessel density","Anti-VEGF therapy","2026-07-24",{"date":265,"type":33},{"date":315,"type":33},"2026-05-23",{"date":317,"type":22},"2026-12-31",{"name":39,"class":40},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":326,"minAge":327,"maxAge":106,"enrollmentInfo":328,"targetDuration":4,"studyType":52,"phases":330,"briefSummary":331,"conditions":332,"keywords":335,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":150},"100647581","transcutaneous-tibial-nerve-stimulation-ttns-patch-in-the-treatment-of-patients-with-lower-urinary-tract-symptoms-luts-after-benign-prostatic-hyperplasia-bph-surgery-100647581","NCT07710794","Transcutaneous Tibial Nerve Stimulation (TTNS) Patch in the Treatment of Patients With Lower Urinary Tract Symptoms (LUTS) After Benign Prostatic Hyperplasia (BPH) Surgery","Transcutaneous Tibial Nerve Stimulation (TTNS) Patch Combined With Behavioral Therapy (BT) Versus Behavioral Therapy in the Treatment of Patients With Lower Urinary Tract Symptoms (LUTS) After Benign Prostatic Hyperplasia (BPH) Surgery: a Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n* 1\\. Male, aged 50 to 80 years. 2. Diagnosis of benign prostatic hyperplasia (BPH) confirmed by IPSS, imaging, PSA, pathology, or other relevant assessments.\n\n  3\\. Previous treatment with transurethral laser enucleation of the prostate for BPH.\n\n  4\\. Persistent overactive bladder symptoms one month after surgery, defined as an average of ≥8 voids per 24 hours documented on a 72-hour voiding diary.\n\n  5\\. Not currently using, or having discontinued at least 14 days prior to enrollment, all related medications (e.g., β3-adrenoceptor agonists, non-selective β-adrenoceptor agonists, or anticholinergics).\n\n  6\\. Medically stable and not requiring hospitalization. 7. Voluntary participation in this clinical study, with written informed consent signed by the participant before study initiation.\n\nExclusion Criteria:\n\n* 1\\. History of urinary tract infection, urinary tract malformation, obstruction, anatomical abnormality, or neurological disorder.\n\n  2\\. Known allergy to electrode gel or skin breakdown that precludes the use of surface electrodes.\n\n  3\\. Presence of psychiatric or cognitive impairment that renders the patient unable to cooperate with the study procedures.\n\n  4\\. Any serious comorbidity or condition that may hinder the patient's participation or increase the risk associated with surgical procedures.\n\n  5\\. Participation in another clinical trial within 3 months prior to screening that could potentially affect the results of this study.\n\n  6\\. Other conditions deemed unsuitable for participation by the investigator.","MALE","50 Years",{"count":329,"type":22},70,[54],"The incidence of lower urinary tract symptoms (LUTS) with persistent overactive bladder (OAB) symptoms after benign prostatic hyperplasia (BPH) surgery ranges from approximately 5% to 35%, meaning that roughly one-third of patients remain troubled by symptoms such as urinary frequency, urgency, and increased nocturia following surgery.Current treatment options are limited. Although behavioral therapy (BT) is recommended as first-line treatment, patient compliance is often poor. Pharmacotherapy is associated with insufficient efficacy and adverse effects such as dry mouth, constipation, and cognitive impairment, which lead to low long-term medication adherence.\n\nTranscutaneous tibial nerve stimulation (TTNS) has been proven effective in improving OAB symptoms and is recommended by multiple guidelines as one of the optional treatment modalities. However, research on its application in patients after BPH surgery remains lacking.The novel transcutaneous tibial nerve stimulation patch device offers the advantages of being non-invasive, portable, and suitable for home-based treatment. Whether combining this device with behavioral therapy can provide additional benefits for patients with refractory lower urinary tract symptoms after surgery needs to be verified through clinical research. Therefore, we plan to conduct this randomized controlled study to evaluate the efficacy and safety of the transcutaneous tibial nerve stimulation patch combined with behavioral therapy.",[333,334],"Lower Urinary Tract Symptoms (LUTS)","BPH (Benign Prostatic Hyperplasia)",[336,337,338],"Transcutaneous Tibial Nerve Stimulation","Lower Urinary Tract Symptoms","After Benign Prostatic Hyperplasia (BPH) Surgery","2026-07-13",{"date":341,"type":33},"2026-07-17",{"date":343,"type":22},"2026-06-20",{"date":345,"type":22},"2027-01-31",{"name":39,"class":40},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":355,"targetDuration":4,"studyType":52,"phases":356,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":150},"100631841","acupuncture-for-postoperative-gastric-emptying-delay-100631841","NCT07505927","Acupuncture for Postoperative Gastric Emptying Delay","Acupuncture for POstoperative Gastric Emptying dElay (APOGEE): A Multicenter Randomized Controlled Trial","APOGEE","Inclusion Criteria:\n\n1. Aged 18-80 years, regardless of sex.\n2. Patients who have undergone partial gastrectomy.\n3. Patients presenting with postoperative gastroparesis symptoms, confirmed by imaging or gastric emptying scintigraphy, and clinically diagnosed with gastroparesis.\n4. No severe cardiac, hepatic, renal, or coagulation dysfunction.\n5. No participation in other interventional clinical trials within the past month.\n6. Able to provide written informed consent and comply with the treatment and follow-up procedures.\n\nExclusion Criteria:\n\n1. Patients with severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or coagulation disorders.\n2. Patients who develop serious postoperative complications after partial gastrectomy, such as anastomotic leakage, gastrointestinal bleeding, or severe infections, or conditions that may affect the assessment of gastric motility, such as ascites or intestinal obstruction.\n3. Patients with a known allergy to acupuncture or with skin damage, infection, or severe scarring at the needle insertion sites that would prevent proper acupoint selection or needling.\n4. Patients with diagnosed psychiatric disorders, cognitive impairment, or those unable to cooperate with treatment procedures, symptom assessment, or follow-up.\n5. Patients who have used medications that may significantly affect gastric motility within the past week and cannot discontinue their use.\n6. Pregnant or breastfeeding women, or individuals with other special physiological conditions that may make them unsuitable for participation in acupuncture research.",{"count":136,"type":22},[54],"This multicenter clinical trial, conducted at Qilu Hospital of Shandong University and collaborating institutions, prospectively assesses the efficacy and safety of acupuncture for postoperative delayed gastric emptying. Eligible participants will be prospectively enrolled and randomized into different groups per the study protocol. The primary endpoint is the reduction in the duration of delayed gastric emptying, while secondary endpoints include the complete resolution of cardinal gastroparetic symptoms, such as abdominal distension, nausea, and vomiting. All study procedures adhere to the ethical standards outlined in the approved protocol.",[359,360],"Gastroparesis Postoperative","Delayed Gastric Emptying Following Procedure",[362,363,364,365],"Gastroparesis","Acupuncture","Delayed Gastric Emptying","partial gastrectomy",{"date":367,"type":33},"2026-07-15",{"date":369,"type":33},"2026-04-01",{"date":371,"type":22},"2028-06-01",{"name":39,"class":40},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":380,"targetDuration":4,"studyType":52,"phases":382,"briefSummary":383,"conditions":384,"keywords":388,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":76},"100644877","intraoperative-longitude-latitude-depth-localization-versus-preoperative-ct-guided-percutaneous-lung-puncture-localization-for-08-2-cm-peripheral-pulmonary-nodules-100644877","NCT07675889","Intraoperative Longitude-Latitude-Depth Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for 0.8-2 cm Peripheral Pulmonary Nodules","Intraoperative Longitude-Latitude-Depth Three-Dimensional Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for the Treatment of 0.8-2 cm Peripheral Pulmonary Nodules: A Multicenter, Randomized, Open-Label, Non-Inferiority Clinical Trial","Inclusion Criteria:\n\n* Clinically diagnosed pulmonary nodule by non-contrast chest CT.\n* Age 18 to 80 years.\n* Expected survival time of at least 12 months.\n* Single peripheral pulmonary nodule with a diameter between 0.8 cm and 2 cm.\n* Chest CT characteristics meeting both of the following criteria:\n\n  1. Solid component proportion ≤50%.\n  2. Located subpleurally or in the outer one-third of the lung parenchyma.\n* Willing to undergo VATS-assisted sublobar resection.\n* No contraindications to pulmonary localization procedures or surgery.\n* Able to understand the study and willing to sign written informed consent.\n\nExclusion Criteria:\n\n* Use of other localization methods or other surgical procedures.\n* Concurrent participation in another clinical study.\n* Pregnancy.\n* Unwillingness or inability to cooperate with participation in this study for any reason.",{"count":381,"type":22},274,[54],"The goal of this clinical trial is to learn whether intraoperative longitude-latitude-depth three-dimensional localization (LLD localization) is non-inferior to preoperative CT-guided percutaneous lung puncture localization for identifying 0.8-2 cm peripheral pulmonary nodules in adults undergoing video-assisted thoracoscopic surgery (VATS)-assisted sublobar resection. It will also evaluate the safety and perioperative effectiveness of the two localization methods. The main questions it aims to answer are:\n\n1. Is the localization accuracy rate of LLD localization non-inferior to that of CT-guided percutaneous lung puncture localization?\n2. Does LLD localization improve perioperative outcomes, including localization time, postoperative recovery, pain, quality of life, and perioperative complication rates?\n\nResearchers will compare LLD localization with CT-guided percutaneous lung puncture localization to determine whether LLD localization provides comparable localization accuracy while reducing procedure-related complications and improving perioperative outcomes.\n\nParticipants will:\n\n1. Be randomly assigned in a 1:1 ratio to either the LLD localization group or the CT-guided percutaneous lung puncture localization group.\n2. Undergo pulmonary nodule localization using the assigned localization method.\n3. Receive VATS-assisted sublobar resection following localization.\n4. Be assessed for localization accuracy, perioperative complications, localization time, postoperative chest drainage tube removal time, oxygenation index, postoperative hospital stay, pain scores, and quality-of-life outcomes.\n5. Complete follow-up assessments at 1, 3, and 6 months after surgery.",[385,386,387],"Pulmonary Nodule, Solitary","Peripheral Pulmonary Nodules","Pulmonary Nodules",[389,390,391,392,393,394,167,395],"Peripheral Pulmonary Nodule","Pulmonary Nodule Localization","Longitude-Latitude-Depth Localization","CT-Guided Percutaneous Localization","Video-Assisted Thoracoscopic Surgery","Sublobar Resection","Non-Inferiority Trial","2026-06-23",{"date":398,"type":33},"2026-06-30",{"date":400,"type":22},"2026-07-01",{"date":402,"type":22},"2028-07-01",{"name":39,"class":40},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":150},"100641112","mcg-for-non-obstructive-myocardial-ischemia-100641112","NCT07657546","MCG for Non-Obstructive Myocardial Ischemia","Magnetocardiography in the Identification of Non-Obstructive Myocardial Ischemia of Patients With Acute Chest Pain","Inclusion Criteria:\n\n* Age 18 years or older;\n* Patients with symptoms of myocardial ischemia such as angina pectoris, who have CAG showing \\\u003C70% stenosis at the most severe site or CTA showing non-severe stenosis\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with absolute or relative contraindications to CFR-loaded myocardial perfusion, including acute myocardial infarction within 48 hours, significant left main coronary artery stenosis, bronchial asthma, and adenosine injection allergy;\n* Patients with Non-ischemic dilated cardiomyopathy, or hypertrophic cardiomyopathy, or moderate or severe valvular disease;\n* Patients with Hemodynamic instability (systolic blood pressure\\\u003C90 mmHg, or who requires vasoactive drugs), or patients with tachyarrhythmia,\n\n  #degree atrioventricular block and above that have not returned to normal;\n* Patients who have severe renal abnormality with eGFR \\\u003C30 ml\u002Fmin, or patients who are on dialysis;\n* Patients with malignant tumors with predicted survival of less than 1 year;\n* Pregnant or breastfeeding women;\n* Patients who are unable to enter the MCG device, who are unable to perform MCG examination due to interference from metal implants or other reasons, or who are deemed by the investigators to be unsuitable for enrollment.",{"count":412,"type":22},3786,"The aim of this prospective study is to identify Non-Obstructive Myocardial Ischemia of patients who have acute chest pain using Magnetocardiography.",[415],"Myocardial Ischemia",[417],"Ischemia with No Obstructive Coronary Arteries","2026-06-21",{"date":420,"type":33},"2026-06-24",{"date":422,"type":33},"2025-04-15",{"date":424,"type":22},"2026-08-30",{"name":39,"class":40},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":433,"minAge":18,"maxAge":4,"enrollmentInfo":434,"targetDuration":436,"studyType":23,"phases":4,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":4},"100642190","tte-study-of-ql1706-in-recurrentmetastatic-cervical-cancer-100642190","NCT07652983","TTE Study of QL1706 in Recurrent\u002FMetastatic Cervical Cancer","Real-World Effectiveness and Safety of Iparomlimab and Tuvonralimab in Recurrent or Metastatic Cervical Cancer: A Target Trial Emulation Study","Inclusion Criteria:\n\n* Participants voluntarily agree to participate in the study and provide written informed consent.\n* Age ≥18 years at the time of signing the informed consent form.\n* Histologically confirmed recurrent or metastatic cervical cancer (FIGO 2018 stage IVB), including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* Disease progression or treatment failure following prior platinum-based chemotherapy.\n* At least one measurable target lesion according to RECIST version 1.1, as assessed by CT or MRI.\n* Estimated life expectancy of at least 3 months.\n* Considered suitable by the investigator for antitumor treatment with Iparomlimab and Tuvonralimab (QL1706), either as monotherapy or in combination with other therapies, and with a planned treatment regimen including QL1706.\n\nExclusion Criteria:\n\n* Histological subtypes including sarcoma, small-cell carcinoma with neuroendocrine differentiation, or other non-epithelial malignancies.\n* History of severe hypersensitivity reaction (Grade ≥3) to Iparomlimab and Tuvonralimab (QL1706) and\u002For any of its excipients.\n* Known additional malignancy that has progressed or required active treatment within the past 3 years.\n* Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive therapy); history of non-infectious pneumonitis requiring steroid treatment, or current pneumonitis.\n* Active infection requiring systemic therapy.\n* Any other medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would make the participant unsuitable for participation in this study.","FEMALE",{"count":435,"type":22},280,"2 Years","The goal of this observational study is to evaluate the effectiveness and safety of Iparomlimab and Tuvonralimab (QL1706)-based therapy in patients with recurrent or metastatic cervical cancer who have experienced disease progression after platinum-based treatment.\n\nThe main questions it aims to answer are:\n\n* Does QL1706-based therapy improve clinical outcomes compared with investigator-selected chemotherapy in patients with recurrent or metastatic cervical cancer?\n* Does the addition of bevacizumab further improve treatment effectiveness?\n* Which patient subgroups are most likely to benefit from QL1706-based therapy? Participants receiving QL1706-based therapy or investigator-selected chemotherapy as part of routine clinical practice will be followed through real-world clinical data collection. Using a target trial emulation framework, the study will compare treatment effectiveness and safety between groups. Clinical characteristics, treatment outcomes, and adverse events will be collected for analysis. In addition, artificial intelligence-based models and multi-omics analyses will be used to identify predictive biomarkers and explore potential mechanisms of treatment response and resistance.",[439],"Recurrent or Metastatic Cervical Cancer",[441,442],"Recurrent or metastatic cervical cancer","Iparomlimab and Tuvonralimab","2026-06-11",{"date":445,"type":33},"2026-06-17",{"date":447,"type":22},"2026-06-15",{"date":244,"type":22},{"name":39,"class":40},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":457,"targetDuration":4,"studyType":52,"phases":459,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":150},"100599800","phase-2-tislelizumab-combined-with-anlotinib-and-nab-paclitaxel-in-iii-resectable-non-small-cell-lung-cancer--a-prospective-single-arm-phase-ii-study-100599800","NCT07089199","Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study","TitAN","Inclusion Criteria:\n\n1. Age 18-75 years old, gender is not limited;\n2. Histologically confirmed Stage III non-small cell lung cancer (AJCC Stage 8th edition)\n3. The tumor is resectable after assessment by the attending surgeon\n4. EGFR\u002FALK mutation negative or unknown (unknown only for squamous non-small cell lung cancer)\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n6. No previous treatment received\n7. At least 1 measurable lesion as defined by RECIST v1.1\n8. Be able to provide the Informed Consent Form (ICF), and be able to understand and agree to abide by the research requirements and assessment schedule\n9. Good organ function; • Patients have not received blood transfusion or growth factor support therapy ≤ 14 days prior to sample collection during the screening period and: Absolute neutral cell count (ANC) ≥1.5 x 109\u002FL Platelet ≥100 x 109\u002FL Hemoglobin ≥90 g\u002FL • Calculated creatinine clearance (CrCl) (Cockcroft-Gault formula) creatinine clearance ≥ 45 mL\u002Fmin Serum total bilirubin ≤1.5 × upper limit of normal (ULN) (patients with Gilbert\\'s syndrome must have total bilirubin \\< 3 × ULN) AST and ALT≤ 2.5 x ULN Patients who did not receive anticoagulant therapy: International standardized ratio or activated partial thromboplastin time ≤ 1.5 × ULN\n10. Women of childbearing age must take a serum pregnancy test within 3 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must agree to use highly effective methods of contraception during the study period and for 120 days after the last dose of the study drug\n\nExclusion Criteria:\n\n1. A history of received treatment for current lung cancer, including radiotherapy and all systemic antitumor agents, including chemotherapy, immunotherapy, targeted therapy or antiangiogenic therapy.\n2. Patients with known EGFR gene mutation, ALK rearrangement, ROS-1 fusion, RET fusion, HER-2 mutation, MET mutation, but if patients with squamous non-small cell lung cancer, the EGFR mutation status and ALK mutation status are unknown, it is not required to conduct tests during screening\n3. There are multiple factors influencing patients taking oral medication (such as inability to swallow, chronic diarrhea, intestinal obstruction)\n4. Allergy to any study drug (Tislelizumab, Anlotinib, albumin-bound Paclitaxel) or excipients.\n5. Imaging shows that the tumor has invaded important blood vessels or the investigator judges that the tumor invasion of important blood vessels during treatment is likely to cause fatal bleeding.\n6. Clinically significant hemoptysis (more than 50 ml per day) within 3 months before the study, or clinically significant bleeding symptoms or obvious bleeding tendency (such as gastrointestinal bleeding, gastric ulcer bleeding, gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above baseline, or suffering from vasculitis, etc.).\n7. Vaccination with attenuated live vaccines within 4 weeks before the first dose or planned vaccination during the study period.\n8. Patients who are expected to be unable to tolerate surgery, such as those with cardiopulmonary insufficiency.\n9. Occurrence of or concurrent other malignancies within the past 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)\\].\n10. Patients with active viral hepatitis requiring treatment as determined by the investigator.\n11. Active autoimmune diseases requiring systemic treatment, or long-term use of high doses of steroids or other immunomodulators, which the investigator assesses as affecting the study treatment.\n12. Unhealed surgical incisions before the start of study treatment (small biopsy incisions can be included).\n13. Active hepatitis B\u002FC infection and human immunodeficiency virus (HIV) infection.\n14. Arterial or venous thrombotic events within 6 months (such as cerebrovascular accident, deep vein thrombosis, pulmonary embolism, etc.) or severe cardiovascular diseases: myocardial ischemia or myocardial infarction above grade II, uncontrolled arrhythmias; heart failure above grade III-IV according to NYHA standards, or left ventricular ejection fraction (LVEF) \\\u003C 50% as indicated by echocardiography.\n15. Interstitial lung disease, uncontrolled systemic medical history, including diabetes, hypertension, acute lung disease, etc.\n16. Active bleeding or coagulation dysfunction (INR \\> 2.0, PT \\> 16s), bleeding tendency or receiving thrombolytic, anticoagulant, antiplatelet therapy; any major surgery requiring general anesthesia within ≤ 28 days before the first dose.\n17. Underlying medical conditions or alcohol\u002Fdrug abuse that are unfavorable for the administration of study drugs, may affect the interpretation of results, or pose a high risk of treatment complications.",{"count":458,"type":22},34,[460],"PHASE2","This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.",[463,464,465,466],"NSCLC","Tislelizumab","Anlotinib","Nab-paclitaxel",{"date":447,"type":33},{"date":469,"type":33},"2025-07-25",{"date":471,"type":22},"2028-07-10",{"name":39,"class":40},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":481,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":52,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":4},"100641690","online-booster-training-system-for-improving-cpr-quality-100641690","NCT07649343","Online Booster Training System for Improving CPR Quality","Improving CPR Quality With Online Booster Training System in Medical Students: A Randomized Controlled Trial","OBS-CPR","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* no CPR training within the past 3 years\n* Full attendance and completion of the initial offline CPR course\n* Voluntary participation and signed informed consent\n* Availability of smart phones, tablets or computers for online training and follow-up\n\nExclusion Criteria:\n\n* Physical limitations preventing high-quality chest compression (e.g., severe carpal tunnel syndrome, spinal diseases, etc.)\n* Prior CPR learning experience or potential access to additional spontaneous CPR booster training after initial training\n* Unavailability to complete follow-up assessments within the study period for any reason.",true,{"count":483,"type":22},210,[54],"Improving CPR Quality with Online Booster Training System in Medical Students: A Randomized Controlled Trial\n\n1. Objective To explore the effect of the online booster training system on cardiopulmonary resuscitation (CPR) skill retention among adult CPR learners.\n2. Participants Medical university students, who have received the standardized offline AHA BLS course.\n\n   Inclusion Criteria\n   * Aged ≥ 18 years\n   * no CPR training within the past 3 years\n   * Full attendance and completion of the initial offline CPR course\n   * Voluntary participation and signed informed consent\n   * Availability of smart phones, tablets or computers for online training and follow-up Exclusion Criteria\n   * Physical limitations preventing high-quality chest compression (e.g., severe carpal tunnel syndrome, spinal diseases, etc.)\n   * Prior CPR learning experience or potential access to additional spontaneous CPR booster training after initial training.\n   * Unavailability to complete follow-up assessments within the study period for any reason.\n3. Randomization Participants will be randomly allocated (1:1) to either of groups using the online system, with an online random number generator (www.randomizer.org). The numbers were randomly assigned to consented participants by a person, who is not a member of the research team.\n\n   Blinding: Outcome assessors, offline training instructors and statistical analysts are blinded. Due to the nature of the intervention, participants are not blinded.\n4. Interventions Intervention group (Online Booster Training Group) Requirements: Within 3 months after initial training, participants should complete full online training session at least once per month.\n\n   Platform: Qilu Online Booster Training System for Adult Cardiopulmonary Resuscitation.\n\n   Contents: Teaching review (video lectures); practice assessment.\n\n   Control group (No Booster Training Group) No booster training of any form was provided. Participants only returned for outcome assessment at the designed time.\n5. Outcomes 5.1 Primary Outcome Excellent CPR, which was defined as at least 90% guideline-compliance for depth, rate and recoil of chest compression.\n\n   5.2 Secondary Outcome (i) compression depth (mm), assessed with the certified CPR manikins (ii) compression rate (per minute), assessed with the certified CPR manikins (iii) Percentage of compression depth \\> 50 mm (iv) Percentage of CC (chest compression) with rate of 100-120\u002Fmin (v) Percentage of CC with complete recoil. (vi) The pass rate of theoretical test\n6. Sample Size Calculation The sample size was estimated based on the primary outcome measure. A previous study showed that the proportion of \"excellent CPR\" without booster training is 88%. We expected to detect a 10% difference in the proportion of excellent CPR between groups. Based on these assumptions, an alpha of 0.05 and a power of 0.8, assuming a dropout of 5%, we will aim to include 105 participants per group, that is, a total of 210 participants.\n7. Statistical Analysis variables will be assessed for normal distribution and reported as means (SD) or medians (IQR), whichever is appropriate. Continuous data will be compared using a Student's t-test or Mann-Whitney U test, whichever is appropriate. Categorical variables will be reported as numbers (%) and compared using χ2 or Fisher's exact tests, whichever is appropriate. All baseline variables and outcome data variables will also be compared between the two study groups using the abovementioned tests. In case of confounding variables, we will correct comparisons on the outcome measures between the study groups for these confounders using analysis of covariance. A p-value of \\\u003C0.05 will be considered statistically significant. Analyses will be performed using SPSS V.25",[487],"CPR Skills","2026-06-09",{"date":490,"type":33},"2026-06-16",{"date":492,"type":22},"2026-06-10",{"date":494,"type":22},"2027-06-10",{"name":39,"class":40},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":433,"minAge":503,"maxAge":106,"enrollmentInfo":504,"targetDuration":4,"studyType":52,"phases":506,"briefSummary":507,"conditions":508,"keywords":511,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":518,"leadSponsor":519,"locationsCount":150},"100643811","a-novel-wearable-transcutaneous-tibial-nerve-stimulation-ttns-device-in-the-treatment-of-patients-with-overactive-bladder-oab-and-nocturia-100643811","NCT07635251","A Novel Wearable Transcutaneous Tibial Nerve Stimulation (TTNS) Device in the Treatment of Patients With Overactive Bladder (OAB) and Nocturia","A Novel Wearable Transcutaneous Tibial Nerve Stimulation (TTNS) Device Combined With Behavioral Therapy (BT) Versus Behavioral Therapy in the Treatment of Patients With Overactive Bladder (OAB) and Nocturia: a Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n1. age ≥20 years old, ≤80 years old, female;\n2. patients with overactive bladder (OAB) symptoms for more than 8 weeks; The inclusion criteria were as follows: voiding frequency ≥8 times in 24 hours, urgency attack ≥1 time in 24 hours, nocturnal voiding ≥2 times (OABSS score ≥6 points), and nocturnal polyuria index (NPi) ≤0.33.\n3. the patient's physical condition is stable and can be treated at home;\n4. All participants volunteered to participate in the study and provided written informed consent before the study began.\n\nExclusion Criteria:\n\n1. Residual urine volume ≥100 mL;\n2. difficulty walking;\n3. urethral stricture;\n4. bladder stones;\n5. bladder cancer;\n6. urinary tract infection;\n7. pregnant, lactating women, women of childbearing age who plan to become pregnant during the study or who do not use safe contraception;\n8. pelvic organ prolapse;\n9. neuropsychiatric disorders (including cerebrovascular diseases) associated with neurogenic bladder;\n10. taking medications for urinary system diseases within 2 weeks before enrollment;\n11. patients with mental and cognitive impairment who are unable to cooperate with treatment;\n12. other conditions considered by the investigator to be inappropriate for study participation.","20 Years",{"count":505,"type":22},80,[54],"Overactive bladder (OAB) is a syndrome with urgency as the main symptom, usually accompanied by frequent urination, nocturia, and sometimes urge urinary incontinence. Globally, the prevalence of OAB in the general population has been reported to be about 20%. Nocturia was defined as the patient waking up at least once during the night to urinate. Among lower urinary tract symptoms, nocturia can significantly affect daily life and quality of life. Reported causes of nocturia include nocturnal polyuria, sleep disorders, circadian rhythm disruption (e.g., circadian rhythm sleep disorders), and reduced bladder capacity. Because overactive bladder (OAB) may be associated with reduced bladder capacity, anticholinergic agents are used as standard therapy in the management of nocturia associated with OAB. However, anticholinergic medications are associated with poor adherence, such as inadequate efficacy and adverse effects (e.g., dry mouth, constipation, and cognitive impairment). Therefore, it is imperative to find alternative therapies for anticholinergic drugs.\n\nPrevious studies have shown that transcutaneous tibial nerve stimulation (TNS) can also significantly improve lower urinary tract symptoms, such as frequency, urgency, incontinence, and nocturia, and is also one of the options for the treatment of OAB. A previous study also demonstrated its improvement in sleep quality in women with nocturia. However, the efficacy of tibial nerve stimulation in the treatment of active bladder with nocturia is still a blank, and further studies are needed.",[509,510],"Overactive Bladder (OAB)","Nocturia",[512,513,514],"transcutaneous tibial nerve stimulation","overactive bladder","nocturia","2026-06-03",{"date":488,"type":33},{"date":492,"type":22},{"date":494,"type":22},{"name":39,"class":40},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":527,"targetDuration":4,"studyType":52,"phases":529,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":539,"locationsCount":150},"100643800","comparison-of-double-tract-and-tubular-gastric-anastomosis-in-proximal-gastric-cancer-100643800","NCT07635836","Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer","Comparison of Gastroesophageal Reflux and Quality of Life Between Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer Patients","Inclusion Criteria:\n\n* Pathologically confirmed gastric adenocarcinoma by biopsy\n* Carcinoma of the upper gastric body or Siewert type II\u002FIII adenocarcinoma of the esophagogastric junction (AEG), with a clinical stage of cT1-3N0-1M0\n* Age 18-75 years, with a performance status (PS) score of 0-2\n* Candidates for planned surgical resection, eligible for either double-tract reconstruction or tubular gastric anastomosis based on preoperative assessment\n* No severe dysfunction of vital organs (liver, kidney, heart, lung, or brain), and no severe infection or uncontrolled chronic diseases\n\nExclusion Criteria:\n\n* Presence of other malignant tumors or severe chronic diseases (e.g., severe diabetes mellitus, chronic kidney disease, decompensated cirrhosis, etc.)\n* Preoperative endoscopic diagnosis of Barrett's esophagus\n* Severe preoperative malnutrition (albumin \\\u003C30 g\u002FL, prealbumin \\\u003C150 mg\u002FL)\n* History of prior upper abdominal surgery, gastrointestinal malformation, or psychiatric disorders\n* Preoperative diagnosis of obstructive motor disorders of the cardia (including achalasia spectrum disorders)\n* Inability to cooperate with or complete the required postoperative examinations",{"count":528,"type":22},52,[54],"This study includes patients diagnosed with proximal gastric cancer (Siewert type II\u002FIII, cT1-3N0-1M0) across six tertiary hospitals, who underwent either double-tract reconstruction (DTR) or tubular gastric anastomosis (TGA). Participants were divided into two groups based on the surgical procedure. We conducted a comparative analysis of postoperative outcomes by evaluating electronic medical records, postoperative gastroscopy, 24-hour esophageal pH monitoring, and relevant rating scales.",[532,533,534],"Gastric Cancer (GC)","Double-tract Reconstruction","Tubular Gastric Anastomosis",{"date":488,"type":33},{"date":537,"type":33},"2026-05-01",{"date":127,"type":22},{"name":39,"class":40},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":547,"targetDuration":4,"studyType":52,"phases":549,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":557,"leadSponsor":559,"locationsCount":150},"100643484","efficacy-of-probiotics-for-oab-patients-with-anxiety-100643484","NCT07635212","Efficacy of Probiotics for OAB Patients With Anxiety","Evaluating the Efficacy of Probiotics as an Adjunct to Behavioral Therapy in Patients With Overactive Bladder (OAB) and Anxiety Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old (inclusive).\n2. Able to understand study-related instructions and independently complete the required questionnaires.\n3. Able to provide written informed consent and willing to comply with all study requirements, including completing diaries\u002Fquestionnaires and refraining from taking any other probiotic or prebiotic supplements during the 3-month study period.\n4. Meet the diagnostic criteria for Overactive Bladder (OAB) as defined by the International Continence Society (ICS) (urgency as the core symptom, with or without urgency urinary incontinence, frequency, and nocturia); have an Overactive Bladder Symptom Score (OABSS) ≥ 6; and have a daytime voiding frequency of ≥ 8 times.\n5. Have a preliminary diagnosis of \"Generalized Anxiety Disorder\" or \"Anxiety state\" assessed by a psychiatrist or trained investigator according to DSM-5 or ICD-10 criteria, or have a Generalized Anxiety Disorder-7 (GAD-7) scale score ≥ 5.\n6. If previously using any over-the-counter medications or other products for anxiety relief (e.g., magnesium, melatonin, anticholinergic drugs) or receiving psychotherapy, these must have been discontinued for at least 4 weeks prior to randomization and must remain completely discontinued throughout the entire study period.\n\nExclusion Criteria:\n\n1. Presence of organic diseases of the urinary system (e.g., urinary tract obstruction, tumors, stones, acute infection, interstitial cystitis, stress urinary incontinence).\n2. Neurogenic bladder caused by neurological diseases or a history of pelvic surgery.\n3. Use of antibiotics, probiotics, or prebiotics within the past 1 month prior to screening.\n4. Any adjustment to medications used for treating OAB or anxiety within the past 2 weeks prior to screening.\n5. Pregnant or lactating women, or individuals with a known allergy to any components of the study preparation.\n6. Suffering from other severe psychiatric\u002Fpsychological disorders or severe systemic diseases (e.g., uncontrolled diabetes mellitus, severe obesity).",{"count":548,"type":22},218,[54],"The goal of this clinical trial is to learn if probiotics can help improve symptoms in adults with overactive bladder (OAB) and anxiety. The main questions it aims to answer are:\n\n1. Does taking probiotics lower the number of times participants need to urinate in a 24-hour period?\n2. Does taking probiotics lower participants' anxiety levels?\n\nResearchers will compare probiotics to a placebo (a look-alike powder that contains no active bacteria) to see if the probiotics work better to treat OAB and anxiety when both groups also use standard behavioral therapy (like bladder training).\n\nParticipants will:\n\n1. Take probiotics or a placebo twice a day for 12 weeks.\n2. Learn and practice bladder training using a manual and educational videos.\n3. Keep a 3-day diary of when they urinate and what they drink at the beginning, middle, and end of the study.\n4. Answer survey questions about their anxiety and quality of life during clinic visits.\n5. Provide urine samples for routine checkups to ensure they do not have infections.",[509],[553,554,513],"probiotics","OAB",{"date":488,"type":33},{"date":400,"type":22},{"date":558,"type":22},"2028-12-31",{"name":39,"class":40},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":233,"enrollmentInfo":568,"targetDuration":4,"studyType":52,"phases":570,"briefSummary":571,"conditions":572,"keywords":574,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":41},"100570728","target-directed-management-of-cerebral-oxygenation-in-patients-after-receiving-ecpr-100570728","NCT06711016","Target-directed Management of Cerebral Oxygenation in Patients After Receiving ECPR","Efficacy and Safety of Target-directed Management of Cerebral Oxygenation in Patients Undergoing Extracorporeal Cardiopulmonary Resuscitation: A Multicenter, Pragmatic, Randomized, Controlled Clinical Trial","TDMCO-ECPR","Inclusion criteria:\n\n1. 18-75 years old\n2. Witnessed in-hospital or out-of-hospital cardiac arrest\n3. Patients who did not achieve return of spontaneous circulation (ROSC) after 15 minutes of conventional cardiopulmonary resuscitation (CPR), or whose ROSC cannot be maintained, and who received ECPR\n4. Time from cardiac arrest to initiation of CPR \\\u003C 10 minutes\n5. The cause of cardiac arrest is expected to be reversible (e.g., hypothermia, acute myocardial infarction\u002Fmyocardial ischemia, malignant arrhythmia, pulmonary embolism, electrolyte abnormalities, hypoxia, anaphylactic shock, hemorrhage\u002Fhypovolemia, drug poisoning, electric shock, etc.)\n\nExclusion criteria:\n\n1. Aortic dissection\n2. Participants with active gastrointestinal bleeding or other conditions with contraindications to anticoagulation\n3. Pregnancy\n4. Severe trauma\n5. Cerebral Performance Category (CPC) score \\> 2 before cardiac arrest, or acute cerebrovascular disease (e.g., suspected or confirmed acute stroke, subarachnoid hemorrhage, etc.)\n6. Terminal diseases, such as malignant tumors, end-stage liver and kidney diseases, severe heart failure (NYHA class III or IV), severe COPD (GOLD class III or IV), etc.\n7. Transfer time from cardiac arrest to extracorporeal membrane oxygenation (ECMO) \\> 90 minutes\n8. Previous history of bilateral femoral artery bypass grafting or artificial vascular replacement, unsuitable for ECMO catheterization",{"count":569,"type":22},654,[54],"Neurological injury remains an important cause of morbidity and mortality in patients with ECPR. At present, the results of three prospective randomized controlled studies on ECPR are inconsistent, and it is inconclusive whether ECPR can improve the neurological outcomes of patients with refractory cardiac arrest. Several study found that extracorporeal membrane oxygenation nonsurvivors can lead toacute brain injury.Further research with a systematic neurologic monitoring is necessary to define the timing of acute brain injury in patients with extracorporeal membrane oxygenation.Moreover, brain injury that occurs during extracorporeal membrane oxygenation therapy is not easy to detect in time because of the use of analgesics, sedatives, and muscle relaxants. Surprisingly, little attention has been paid to the role of cerebral perfusion and oxygenation. Moreover,the features of cerebrovascular pathophysiology and optimal management strategies are still vague.\n\nTherefore multimodal neuromonitoring may be a valuable tool for detecting brain injury in patients with extracorporeal membrane oxygenation and providing early intervention guidance.\n\nMultimodal neuromonitoring, integrating tools such as near-infrared spectroscopy (NIRS), transcranial Doppler, and continuous electroencephalography, may enable early detection of brain injury and guide targeted interventions.\n\nHypothesis: Multimodal neuromonitoring combined with a standard care management will increase the proportion of patients achieving survival with favorable neurological outcome (Cerebral Performance Category \\[CPC\\] 1-2) at 30 days compared with standard care without protocolized neuromonitoring.\n\nPrimary Objective: To test whether a multimodal neuromonitoring strategy improves 30-day survival with favorable neurological outcome (CPC 1-2) in adult patients with refractory cardiac arrest treated with ECPR.",[573],"Cardiac Arrest",[575,576,577,578],"Multimodality Neuromonitoring","ECPR","Out-of-hospital Caridac arrest","In-Hospital Cardiac Arrest",{"date":580,"type":33},"2026-06-08",{"date":582,"type":33},"2025-04-22",{"date":584,"type":22},"2028-07-30",{"name":39,"class":40},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":52,"phases":595,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":150},"100580259","colistin-methanesulfonate-sodium-inhalation-for-prophylaxis-of-ventilator-associated-pneumonia-civap-a-prospective-multicentre-double-blind-randomized-placebo-controlled-trial-100580259","NCT06834971","Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial","CIVAP","Participants will be enrolled if they meet the following criteria:\n\n1. Age ≥18 years;\n2. Mechanical ventilation for more than two consecutive days (48 hours);\n3. Patient has high-risk factors for multidrug-resistant bacterial infections, which meet any of the following criteria:\n\n(1)History of antibiotic exposure within 30 days; (2)Hospitalization time\\>5 days (120 hours); (3)Septic shock; (4) ARDS; (5)Accept renal replacement therapy; (6)Previous colonization of multidrug-resistant bacteria; 4. Informed consent of the patient or a proxy was written.\n\nParticipants will be excluded in case of:\n\n1. Suspected or confirmed VAP at the inclusion day;\n2. Patient ventilated through an endotracheal tube for more than four consecutive days (96 hours);\n3. Expected that endotracheal intubation will be removed within the next 24 hours;\n4. Tracheostomy;\n5. Allergy to CMS;\n6. Patients has polymyxins medication history within 7 days or clinical indication for systemic CMS therapy at the inclusion day;\n7. Chronic kidney failure with baseline glomerular filtration ≤30 mL\u002Fmin or Stage 3 classification AKI (KDIGO) (excluding patients undergoing renal replacement therapy);\n8. Expected survival time not exceeding 48 hours;\n9. Pregnancy or breastfeeding period;\n10. Patients previously included in this study or are using any inhaled antibiotics or are participating in other clinical studies within 30 days.",{"count":594,"type":22},508,[54],"Previous studies have identified Acinetobacter baumannii (AB), Pseudomonas aeruginosa (PA), and Klebsiella pneumoniae (KP) as the predominant pathogens responsible for ventilator-associated pneumonia (VAP). The challenge of drug resistance, especially against carbapenem is intensifying, with variations noted across different regions. Multidrug-resistant organisms associated VAP (MDR-VAP) are increasing in frequency and are associated with significant morbidity, mortality, therefore imposes a heavy burden on the healthcare system. Colistin methanesulfonate sodium (CMS) has shown effectiveness against gram-negative bacteria, including carbapenem-resistant organisms (CRO) such as carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Klebsiella pneumoniae (CRKP). This trial aims to evaluate the efficacy of a 3-day course of inhaled CMS in lowering the incidence of VAP among patients undergoing invasive mechanical ventilation for at least two days and at high risk of MDR-VAP.",[598],"Ventilator-Associated Pneumonia (VAP)",[600,601,602],"colistin","prevention","nebulization","2026-05-16",{"date":605,"type":33},"2026-05-19",{"date":607,"type":33},"2025-07-15",{"date":609,"type":22},"2026-12",{"name":39,"class":40},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":52,"phases":620,"briefSummary":621,"conditions":622,"keywords":624,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":150},"100631010","prophylactic-ps-placement-to-prevent-pancreatitis-after-endoscopic-transpapillary-gpc-for-cholelithiasis-with-concomitant-choledocholithiasis-100631010","NCT07495111","Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis","Prophylactic Pancreatic Stent Placement to Prevent Pancreatitis After Endoscopic Transpapillary Gallbladder-preserving Cholecystolithotomy for Cholelithiasis With Concomitant Choledocholithiasis","Inclusion Criteria:\n\n1. Patients aged 18 years or older;\n2. Patients with gallbladder stones and common bile duct (CBD) stones confirmed by ultrasound and\u002For MRCP or other imaging modalities (CT\u002FMRI);\n3. Patients with every gallbladder stone ≤1 cm in diameter or sludge-like stones;\n4. Patients without a history of gastrointestinal reconstruction surgery,cholecystectomy or previous biliary surgery, includes ERCP;\n5. The morphology and size of the gallbladder are essentially normal and the thickness of the gallbladder wall is ≤3 mm;\n6. Patients with at least one of the following high-risk factors for post-ERCP pancreatitis (PEP): suspected sphincter of Oddi dysfunction (SOD), female sex, history of pancreatitis, difficult cannulation (defined as ≥5 cannulation attempts or ≥5 minutes of cannulation time), pancreatic duct contrast injection, age \\\u003C35 years, non-dilated extrahepatic bile duct, no history of chronic pancreatitis, normal serum bilirubin, precut sphincterotomy, biliary balloon dilation, incomplete bile duct stone clearance, or intraductal ultrasound ;\n7. Patients who voluntarily provide signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with any of the following diagnoses: chronic atrophic cholecystitis, porcelain gallbladder, suspected gallbladder malignancy, or Mirizzi syndrome;\n2. Patients with ectopic duodenal papilla or congenital pancreaticobiliary malformations;\n3. Patients unfit for ERCP endoscopic treatment due to severe systemic diseases;\n4. Patients with severe coagulation dysfunction (defined as an International Normalized Ratio \\[INR\\] \\>1.5) or significant thrombocytopenia (platelet count \\\u003C50×10⁹\u002FL);\n5. Pregnant women;\n6. Patients with guidewire entry into the pancreatic duct ≥3 times during the procedure;\n7. Patients with allergies to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs);\n8. Patients with congenital or acquired absence of the rectum;\n9. Patients with severe acute pancreatitis",{"count":619,"type":22},88,[54],"In this multicenter, randomized trial, patients with cholelithiasis with concomitant choledocholithiasis based on inclusion and exclusion criteria will be randomly assigned to receive rectal indomethacin alone or the combination of indomethacin plus a prophylactic pancreatic stent after endoscopic transpapillary gallbladder-preserving cholecystolithotomy.Clinical data and patient-reported outcomes are regularly collected at baseline and during follow-up periods. The study aims to analyze the impact of pancreatic duct stent implantation on the incidence of post-ERCP pancreatitis in gallstone patients treated with ERCP-GPC by comparing the efficacy differences between the experimental and control groups. Additionally, the study investigate the effects of pancreatic duct stent placement post-ERCP on other postoperative complications, conduct a comparative analysis of the economic benefits of placing versus not placing pancreatic duct stents after ERCP, and develop effective clinical strategies for preventing pancreatitis after gallbladder-preserving stone extraction in gallstone patients.",[623],"Cholelithiasis Associated With Common Bile Duct Stones",[625,626,627,628],"Cholelithiasis with Concomitant Choledocholithiasis","Endoscopic Transpapillary Gallbladder-preserving Cholecystolithotomy","post-ERCP pancreatitis","Randomized Controlled Trial (RCT)","2026-05-14",{"date":631,"type":33},"2026-05-18",{"date":633,"type":33},"2025-12-01",{"date":635,"type":22},"2028-06",{"name":39,"class":40},""]